VistaGen Therapeutics Inc (VTGN)

[Fress]

Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A

Know what you own this stock can move hundreds of percentage points on the catalysts listed below.

This my number 1 core holding I'm investing in mental health and like how this company is creating drugs that are fast acting and have very low side effects compared to the standard of care today which only works SSRI's 20-30% of time takes months to work and has extremely high side effects. These are multi billion dollar markets company very likely could get bought like Sage where Biogen bought them out for 1.5 Billion last year.

Reality is a quarter to have the worlds population is suffering from Depression & Anxiety! Vistagen is a disruptor for the industry and a multi billion dollar market cap in the making by next year. Just load up and hold for 12-24 months that way when you sell you pay way less on taxes. Thats what I'm doing with VTGN I own close to 500K shares across multiple accounts and will keep buying I made millions this last year. And will make millions on this particular investment. You can make book on that!

don’t say this often, but VTGN is almost a lock to be at $10 by end of year. Great CEO, excellent leadership, smart execution of their plan and a great product on the horizon! PH94B. And evidenced by their solid stock price on a very down day.

I have had multiple discussions with Mark McPartland VP of corporate development. I have done my DD on this stock. Anyone who is in now and sells below $20 is a fool. This stock will make you a lot of money if you’re patient. PH94B is the real deal.


VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 1.7 billion market cap early clinical trials. 190 million cash
$MMEDF 1.1 billion market cap.
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 315 million market cap Phase 3 ready. (nasdaq)
115 million in cash


$VTGN